Background -Diffuse panbronchiolitis is a chronic infection ofthe lower respiratory tract common among the Japanese people, with a persistent Pseudomonas aeruginosa infection in the late stage and sustained neutrophil retention in the airways. The long term effect of erythromycin was examined retrospectively in a group of patients with diffuse panbronchiolitis, with and without P aeruginosa infection, and the relationship between drug-induced bacterial clearance and clinical improvement was investigated. Methods -The history, daily volume of sputum, type of organisms in sputum cultures, pulmonary function tests, arterial blood gas tensions, and chest radiographs were compared in 16 patients with diffuse panbronchiolitis with P aeruginosa infection and 12 without. The total and differential cell counts in the bronchoalveolar lavage (BAL) fluid were compared in 14 ofthe 28 patients (five ofwhom were infected with P aeruginosa) before and after 1-12 months of treatment with erythromycin (600 mg/day). The outcome oftreatment in patients showing clearance of organisms on repeated sputum cultures was compared with that in those demonstrating persistence of bacteria in the sputum and patients with normal flora. Results -Erythromycin improved respiratory function and arterial blood gas tensions irrespective of the presence or absence of P aeruginosa in the sputum.
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Treatment also resulted in a reduction in the BAL fluid total cell count and the percentage of neutrophils in both groups of patients. There were no differences between patients in whom the bacteria cleared and those with persistent bacteria or patients with a normal flora with regard to the degree of improvement of respiratory function, arterial blood gas tensions, and BAL fluid cell composition. visit to take the medication every eight hours and were provided with a four week supply at each visit. They were instructed to return any remaining tablets on each visit so that the number of the remaining tablets could be checked. None were treated with corticosteroids or antibiotics other than erythromycin during the course of the study.
SPUTUM CULTURE
Sputum culture was performed every 1-3 months before enrolment and during treatment to detect the organism causing airway infection or significant pathogens. The purulent sputum was solubilised in semialcaliproteinase (Sputazym®, Kyokuta Co, Tokyo, Japan) and quantitative examination of the bacteria was achieved through a tenfold serial dilution. The number of bacteria was expressed in colony forming units.2"22 P aeruginosa was identified using the automicrobic system (Vitek Inc, USA).
BRONCHOALVEOLAR LAVAGE
After obtaining informed consent intramuscular atropine (05 mg) was administered followed by local anaesthesia of the airway with 2% lignocaine. Examination of the airway was performed with a flexible fibreoptic bronchoscope (Olympus, BF-P20 type; Olympus Corporation, Tokyo, Japan). The bronchoscope was wedged into one of the subsegmental bronchi of the right middle lobe and 150 ml sterile 0 9% NaCl was infused at 37°C in three 50 ml aliquots and gently aspirated immediately after each infusion. The recovered BAL fluid was pooled, passed through a double layer of gauze to remove gross mucus, then centrifuged. The aliquot was then diluted to a concentration of 1 x 105 cells/ml and 0-2 ml suspension was spun down onto a glass slide at 1100 rpm for two minutes using a Cytospin cytocentrifuge (Shandon Instruments, Sewickley, Pennsylvania, USA). Slides were then dried and stained using the May-Giemsa method. More than 200 cells were identified using a photomicroscope. DATA 
ANALYSIS
Data were expressed as mean (SE). Differences between groups were compared using the two tailed unpaired Student's t test and MannWhitney U test. Within group differences before and after treatment were compared using the two tailed paired Student's t test or Wilcoxon signed rank test when the Bartlett's test showed non-uniformity of the variance. One way analysis of variance was used for multiple group comparisons. A probability of less than 5% was considered to be statistically significant.
Results

CLINICAL FINDINGS
Patients with diffuse panbronchiolitis were divided into two groups as shown in table 1.
Group A consisted of 16 patients (11 men) of mean age 43 (5) years with P aeruginosa in- FEVI (7) FEV, (V0) Pao2 After 92-4 (4 9)**** 2-10 (0-19)*** 70-3 (4.1)**** 11-2 (0.37)**** 5-6 (0-11) Percentage improvement (%) 50-1 14-1 (4-6)
13-3 (5 1) VC =vital capacity; FEV, forced expiratory volume in one second; Pao2, Paco2 arterial oxygen and carbon dioxide tensions. * p<0-001, ** p<0-005, * p<0 01, **** p<0-05 compared with the finding before erythromycin therapy. NS =not significant. FEVI (7) FEVI ( Percentage improvement (G) 58 1 98-0 (42 0)t 27-7 (7 I)t 9 3 (9 5) VC =vital capacity; FEV, =forced expiratory volume in one second; Pao,, Paco2 =arterial oxygen and carbon dioxide tensions.
* p<0-001, ** p<0-005, *** p<001, **** p<0-05 compared with the finding before erythromycin therapy. ). There were no significant differences in the total cell number or the percentage of neutrophils and alveolar macrophages in BAL fluid between the two groups before and after treatment with erythromycin. Figure 2 shows the effect of erythromycin therapy on BAL fluid parameters. In the group in whom the bacteria cleared (n = 7), treatment with erythromycin significantly reduced the mean total cell number from a control value of 24*3 cases without P aeruginosa infection. Treatment with erythromycin improved the prognosis of patients with diffuse panbronchiolitis and increased the 10 year survival rate to more than 90%.2°Erythromycin caused a significant improvement in clinical symptoms, the chest radiograph, respiratory function tests, and arterial blood gas tensions compared with those treated with a new quinolone antibacterial agent for more than three months26 or with ampicillin for three months. 27 The Research Project Team of the Ministry of Health and Welfare for Specific Disease in Japan recently conducted a double blind comparative study with placebo on the use of erythromycin in diffuse panbronchiolitis. Treatment for three months produced a significant clinical improvement.28 In these reports the effect of erythromycin therapy was investigated only at three month intervals. We examined retrospectively the clinical benefits of this treatment for 12 months and the result extensively confirmed the previous reports. Furthermore, no previous study has compared the effect of erythromycin in patients with and without P aeruginosa infection. In our study it was of interest that, irrespective of P aeruginosa infection, the change in respiratory function tests and arterial blood gas tensions before and after erythromycin therapy made no significant differences to the rate of improvement in all parameters. This result shows that erythromycin may be effective in diffuse panbronchiolitis even if the patient is already colonised with P aeruginosa, and the prognosis is good regardless of P aeruginosa infection. However, since this study was performed retrospectively and was restricted to 12 months, the actual course of the chronic disease is difficult to predict. We therefore believe that a long term prospective study should be performed in the future.
In this study treatment with erythromycin was clinically effective whether or not there was bacterial clearance, as P aeruginosa was cleared in seven of the 16 patients (43 8%) although the maximum therapeutic serum and sputum concentrations of the drug at an oral dose of 600 mg/day are below the minimum inhibitory concentration for P aeruginosa.29 It has also been reported that P aeruginosa is often cleared with a clearance rate of 25-9% (seven of 25), 23 and 80% (four of five).29 This could not be confirmed by our study, although many investigators have reported that the effect of erythromycin is mediated through its action on the causative bacteria -for example, inhibition of elastase production by P aeruginosa,"'30 reduction of bacterial adherence correlating with reduced production of pilli of P aeruginosa,3" and the destruction of P aeruginosa biofilm.27'2 The destructive effect of macrolides on the biofilm has recently attracted particular attention. Interestingly, erythromycin therapy reduced sputum volume independent ofbacterial clearance. Such an effect may be mediated by the inhibitory effect of erythromycin on respiratory glycoconjugate secretion"3 or airway hypersecretion. 34 Treatment with erythromycin reduced the total cell number and the percentage of neu- In conclusion, our results indicate that treatment with erythromycin produces clinical improvement in patients with diffuse panbronchiolitis independent of P aeruginosa infection. Although the mode of action was not investigated in the present study, our results suggest that erythromycin may act through its anti-inflammatory properties rather than through its antibacterial effect. Further prospective studies are required to confirm these findings.
